STAT3 and ovarian carcinoma: In ovarian cancer, BP1003 has demonstrated significant anti-tumor effects by reducing STAT3 levels, which in turn decreases cell viability, migration, and spheroid formation, especially when combined with chemotherapy agents like paclitaxel and 5-fluorouracil.